Presentations by Event

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function

Onufrak NJ, Rubino CM, Ambrose PG, Isaacs R, Srinivasan S and O'Donnell J (ECCMID 2019)

Program(s): durlobactam (etx2514)

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Srinivasan S (ECCMID 2019))

Program(s): durlobactam (etx2514)

Efficacy of Cefpodoxime Proxetil and ETX0282 in a Murine UTI Model with E. coli and K. pneumoniae

Weiss WJ, Carter K, Pulse ME, Nguyen P, Valtierra D, Peterson K, Tommasi R, Mueller JP, O'Donnell J (ECCMID 2019)

Program(s): etx0282

Discovery of a Novel Series of Penicillin-Binding Protein 3 Inhibitors as Monotherapy for Pseudomonas aeruginosa Infections: Rational Design of Biochemical Potency and Bacterial Permeation

Durand-Reville T (ECCMID 2019)

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Recent Global Enterobacteriaceae Isolates from Urinary Tract Infections

McLeod S, Moussa S, Huband M, Mueller J, Tommasi R and Miller A (ECCMID 2019)

Program(s): etx0282

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Global Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M, Tommasi R and Miller A (ECCMID 2019)

Program(s): durlobactam (etx2514)

The Susceptibility of Sulbactam/ETX2514 and Comparators to Global Isolates of Acinetobacter baumannii

Seifert H, Stefanik, D, Muller C, Higgins P, Kresken M and Miller A (ECCMID 2019)

Program(s): durlobactam (etx2514)

ETX2514SUL (Sulbactam/ETX2514) for The Treatment of Acinetobacter baumannii Infection

Isaacs R (IDWeek 2018)

Program(s): durlobactam (etx2514)

Addressing the Challenge of Gram-negative Permeation in Antibacterial Discovery

Thomas Durand-Reville, ASM Microbe 2018

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Clinical Isolates of Acinetobacter baumannii, Including Extensively Drug-Resistant (XDR) Isolates Expressing OXA-237

Sarah McLeod, ASM Microbe 2018

Program(s): durlobactam (etx2514)

Evaluation of Pharmacokinetics/Pharmacodynamics of the Novel β-lactamase Inhibitor, ETX2514, in Combination with Sulbactam Against Acinetobacter baumannii

John O'Donnell, ASM Microbe 2018

Program(s): durlobactam (etx2514)

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Extended Spectrum β-lactamase (ESBL)- and Carbapenemase-Expressing Enterobacteriaceae Isolated From Recent Urinary Tract Infections

Sarah McLeod, ASM Microbe 2018

Program(s): etx0282

Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Adult Subjects

K.A. Rodvold (University of Illinois at Chicago), ASM Microbe 2018

Program(s): durlobactam (etx2514)